Talphera (TLPH) Non Operating Income (2010 - 2026)
Talphera (TLPH) posted Non Operating Income of -$388000.0 for Q2 2026, down 127.87% on a QoQ basis from $1.4 million in Q1 2026, and down 290.2% year-over-year from $204000.0 in Q2 2025.
Analysis
Talphera (TLPH) Non Operating Income (2010 - 2026) Analysis & Trends
Talphera has reported Non Operating Income for 17 years, with the latest figure at -$388000.0 in Q2 2026.
- On a quarterly basis, Non Operating Income fell 290.2% year-over-year to -$388000.0 in Q2 2026; TTM through Jun 2026 was -$329000.0, a 116.65% decrease from a year earlier, with the FY2025 full-year figure at -$879000.0, down 139.1% from the prior year.
- Non Operating Income was -$388000.0 for Q2 2026 at Talphera, down from $1.4 million in the prior quarter.
- The five-year high for Non Operating Income was $84.3 million in Q2 2022, with the low at -$1.0 million in Q3 2025.
- Average Non Operating Income over 5 years is $5.2 million, with a median of $250000.0 recorded in 2025.
- The sharpest annual moves came in 2022 and 2025: Non Operating Income soared 49765.68% in 2022, then tumbled 356.06% in 2025.
- Over 5 years, Non Operating Income stood at -$51000.0 in 2022, then tumbled by 345.1% to -$227000.0 in 2023, then soared by 596.04% to $1.1 million in 2024, then tumbled by 128.33% to -$319000.0 in 2025, then declined by 21.63% to -$388000.0 in 2026.
- The last three Non Operating Income figures came in at -$388000.0 (Q2 2026), $1.4 million (Q1 2026), and -$319000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | -73.00 Mn |
| 2 | Gilead Sciences | 180.02 Bn | 176.84 Bn | 6.22 Bn | 387.00 Mn |
| 3 | Vertex Pharmaceuticals | 131.54 Bn | 123.69 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.96 Bn | 73.96 Bn | 3.93 Bn | 234.30 Mn |
| 5 | Argenx Se | 60.23 Bn | 55.04 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.85 Bn | 48.72 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.13 Bn | 29.82 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Biogen | 31.88 Bn | 30.59 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.23 Bn | 29.23 Bn | 1.16 Mn | - |
| 10 | Talphera | 93.28 Mn | 93.28 Mn | - | -388,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -388,000.00 |
| Mar 31, 2026 | 1.39 Mn |
| Dec 31, 2025 | -319,000.00 |
| Sep 30, 2025 | -1.01 Mn |
| Jun 30, 2025 | 204,000.00 |
| Mar 31, 2025 | 250,000.00 |
| Dec 31, 2024 | 1.13 Mn |
| Sep 30, 2024 | 396,000.00 |
| Jun 30, 2024 | 443,000.00 |
| Mar 31, 2024 | 283,000.00 |
| Dec 31, 2023 | -227,000.00 |
| Sep 30, 2023 | 1.89 Mn |
| Jun 30, 2023 | -456,000.00 |
| Dec 31, 2022 | -51,000.00 |
| Sep 30, 2022 | -105,000.00 |
| Jun 30, 2022 | 84.27 Mn |
| Mar 31, 2022 | 321,000.00 |
| Dec 31, 2021 | 258,000.00 |
| Sep 30, 2021 | 258,000.00 |
| Jun 30, 2021 | 169,000.00 |